PJT

jak kto Ci poda ? Jak nie poda to ja zdobede

no niektorym pomagam to musze byc kompetentny -- 13 lis 2013, 00:37 -- wyslac ta ksiazke do Ciebie, przeczytasz i odeślesz nasępnej osobie ? I się wpisz z dedykacją...

mam jeszcze inną, ale nie mam skana -- 13 lis 2013, 00:34 --

Hania hej :*

nie wiem czy Marcin bedzie byl w berlinie na imprezie i zalatany jest

proboje sie uczyc

jeszcze sie nie zdecydowalem ale raczej bede :)

ile śpisz teraz ?

Variable, lepiej ?

rzecz materializm

racja

to coś nas łączy

co to znaczy 'wyjsc z tego wszystkiego' ? :)

hej miski MM jaki masz problem?

uzywam 3mm -- 12 lis 2013, 22:55 -- jak o siebie dbam, bo ostatnio nie

mam kawalek na karaoke dla siebie, co myslisz grzyb ?

pompki to ja chcialbym moc robic nie widziales mojej zmasakrowanej reki, candy widziala, mam neuropatie nerwu łokciowego x2

ja mam teraz w hooj fatu na brzuchu nic by mi nie dal taki trening

czemu ?

kupmitrumne, brawo za odwage, jest slicznie

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists [2005, 17(2):71-75] Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't DOI: 10.1080/10401230590932335 Abstract BACKGROUND: Generalized anxiety disorder (GAD) is characterized by anxiety, and also frequently associated with depressive symptoms. Benzodiazepines have commonly been used in the treatment of GAD, but are not effective antidepressant agents. In this study, we determined whether the selective serotonin reuptake inhibitor escitalopram, was effective across different subgroups and outcomes (anxious symptoms, depressive symptoms, and quality of life). METHODS: Three randomized, placebo controlled studies of escitalopram in GAD have employed a similar design, allowing for pooling of the data. The primary efficacy measure was the Hamilton Anxiety Scale (HAMA). General linear models were used to determine the efficacy of escitalopram across different subgroups and outcomes. RESULTS: Escitalopram was efficacious for GAD on a range of measures of both anxiety and depression, and improved the associated impairment in quality of life. There was no significant interaction of effects on the HAMA with demographic or clinical variables. Furthermore, escitalopram was efficacious on both primary and secondary scales in the subgroup of subjects with above-median severity of depressive symptoms at baseline (HAMD-17 > 12). CONCLUSIONS: Escitalopram reduces anxiety and depressive symptoms in GAD, and improves quality of life. It is equally effective in GAD patients, with an above-median level of depressive symptoms. Further research is needed to determine whether these results can be extrapolated to GAD patients with comorbid major depression. -- 12 lis 2013, 17:25 -- nie zaszkodzi raz jeszcze :***

dla Pati i innych escitalopramowcow Stahl SM, Gergel I, Li D Neuroscience Education Institute,Carlsbad, CA, USA. smstahl@neiglobal.com The Journal of Clinical Psychiatry [2003, 64(11):1322-1327] Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't Abstract Highlight Terms Diseases(6) Chemicals(4) BACKGROUND: Escitalopram, the therapeutically active isomer of the racemic selective serotonin reuptake inhibitor antidepressant citalopram, has shown significant anxiolytic effects in placebo-controlled clinical trials of social anxiety disorder, generalized anxiety disorder, and anxiety symptoms associated with major depression. This study evaluated the safety and efficacy of escitalopram in outpatients diagnosed with panic disorder. METHOD: Male and female outpatients between 18 and 80 years of age meeting DSM-IV criteria for panic disorder, with or without agoraphobia, were randomly assigned to 10 weeks of double-blind treatment with escitalopram, citalopram, or placebo in a study conducted from September 1999 to July 2001. The primary measure of efficacy was panic attack frequency at week 10 relative to baseline, as assessed by the Modified Sheehan Panic and Anticipatory Anxiety Scale. RESULTS: A total of 366 subjects (128 escitalopram patients, 119 citalopram patients, and 119 placebo patients) received at least 1 dose of double-blind treatment. The frequency of panic attacks was statistically significantly improved (p =.04), and the increase in percentage of patients with zero panic attacks reached borderline significance (p =.051), in the escitalopram-treated group relative to the placebo-treated group. Both escitalopram and citalopram statistically significantly reduced panic disorder symptoms and severity versus placebo at endpoint (p =.05), as measured by the Panic and Agoraphobia Scale total score, the Clinical Global Impressions scale, the Patient Global Evaluation, and the Quality of Life Enjoyment and Satisfaction Questionnaire. Treatment with escitalopram was safe and well tolerated, with a similar incidence of the most common adverse events for the escitalopram and placebo groups. The rate of discontinuation for adverse events was 6.3% for escitalopram, 8.4% for citalopram, and 7.6% for placebo. CONCLUSION: Escitalopram is efficacious, safe, and well tolerated in the treatment of panic disorder.

Zgadzam się z większością tego co napisała Kasiątko.

escitalopram to nowsza wersja citalopramu ktory byl wprowadzony na rynek z mysla o osobach starszych, bo nie ma praktycznie skutkow ubocznych, nie liczac tych zwiazanych ze zwrotnym wychwytem. escitalopram to prawoskrętny enancjomer citalopramu ktory ma jeszcze mniej skutkow ubocznych ps Hania przejzałaś ?